Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LioCyx-M in Recurrent HBV-Related HCC Post-Liver Transplant
NCT04677088Phase 1Unknown
- Start
- Mar 2018
- Primary completion
- Feb 2020
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liocyx-m in hepatocellular carcinoma (HCC). Primary endpoint: Safety evaluation of the TCR-T treatment at 28 days. Status: unknown.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04677088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677088.